1. Published Name of the Standard for which request is being made (if previously published)

HL7/NCPDP Informative Document: Pharmacist Consultation Note, Release 1- US Realm

2. Standards Material/Document


3. Date of Request

Feb 27, 2023

4. Use Period

5. Reason for extension, timeline, and actions

6. Original Publication Date

7. End date of the current STU period

8. Length of the requested extension

9. Review Process

10. HL7 Work Group making this request and date


10a. Requesting WG Date

Feb 27, 2023

11. URL of approval minutes


12. HL7 Product Management Group

12a. Management Group Date of Approval

13. URL of approval minutes

14. Is the artifact ready for final publication?


15. If not ready, please describe remaining steps.

16. Tool name used to produce the machine processable artifacts in the IG

not applicable

17. The name of the “IG artifact” within the context of the above mentioned tool.

not applicable

18. Balloted Name of the standard for which request is being made

HL7/NCPDP Informative Document: Pharmacist Consultation Note, Release 1- US Realm

19. Requested name for published standard. See Naming Examples

HL7/NCPDP Informative Document: Pharmacist Consultation Note, Release 1

19a. Specification Feedback Name (For Search in Jira)

20. If CMET, list IDs balloted

21. Project Insight Number


22. Document Realm

US Realm

23. Ballot cycle in which the document was successfully balloted


25. Affirmative


26. Negative


27. Abstentions


28. Not Returned


29. Total in ballot pool


30. Date on which final document/standards material was supplied to HQ

Feb 27, 2023

31. URL of publication material/ SVN repository


32. Publishing Facilitator

Scott Robertson

33. Special Publication Instructions

34. URL of ballot reconciliation document


35. Has the Work Group posted its consideration of all comments received in its reconciliation document on the ballot desktop?


36. Substantive Changes Since Last Ballot?


37. Product Brief Reviewed By

Pharmacy WG

38. Date Product Brief Reviewed

Feb 27, 2023

39. Has the Product Brief changed?

40. Family


41. Section

Clinical and Administrative Domains, Implementation Guides

42. Topic


43. Please Describe the Topic

Guidance on the use of C-CDA Consultation Note and C-CDA on FHIR for a Pharmacist Consultation Note

44. Product Type


45. Parent standard

HL7 Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm) Standard for Trial Use Release 2.1

C-CDA on FHIR 1.1.0 - (FHIR R4) STU Release 1.1 Consultation Note Profile

46. Parent Standard Status


47. Update/replace standard


48. Common name/search keyword

pharmacy consult note, pharmacist consult note, consultant pharmacist consultation note

49. Description

50. Stakeholders

51. Vendors

Health Care IT

52. Providers

Healthcare Institutions (hospitals, long term care, home care, mental health)

53. Benefits

54. Implementations/Case Studies

55. Development Background